AbCellera Biologics Inc. (ABCL)
| Market Cap | 4.47B +150.7% |
| Revenue (ttm) | 66.17M +101.3% |
| Net Income | -164.66M |
| EPS | -0.55 |
| Shares Out | 324.05M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,075,087 |
| Open | 13.72 |
| Previous Close | 13.74 |
| Day's Range | 13.21 - 13.88 |
| 52-Week Range | 2.75 - 15.02 |
| Beta | 1.41 |
| Analysts | Strong Buy |
| Price Target | 16.70 (+21.19%) |
| Earnings Date | Nov 9, 2026 |
About ABCL
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lil... [Read more]
Financial Performance
In 2025, AbCellera Biologics's revenue was $75.13 million, an increase of 160.56% compared to the previous year's $28.83 million. Losses were -$146.41 million, -10.10% less than in 2024.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for ABCL stock is "Strong Buy." The 12-month stock price target is $16.7, which is an increase of 21.19% from the latest price.
News
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026.
AbCellera initiated with an Overweight at JPMorgan
JPMorgan analyst Brian Cheng initiated coverage of AbCellera (ABCL) with an Overweight rating and $17 price target The firm believes the stock “stands at a major value inflection point” following…
AbCellera resumed with a Neutral at Goldman Sachs
Goldman Sachs resumed coverage of AbCellera (ABCL) with a Neutral rating and $13 price target Goldman resumed coverage of the biotechnology sector, saying the group has continued to outperform despite...
AbCellera to present Phase 2 Data for ABCL635 at IMS Congress on Menopause
AbCellera (ABCL) “announced an upcoming oral presentation of Phase 2 data on ABCL635 at the International Menopause Society 20th World Congress on Menopause, to be held September 30 to October…
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026.
AbCellera Biologics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
ABCL635, a novel NK3R antibody, demonstrated superior efficacy and safety in phase II for VMS, with rapid progress toward phase III and strong commercial potential. The company is expanding its pipeline and leveraging its antibody platform for future growth.
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026.
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants.
AbCellera announces $200M common stock, warrants offering
AbCellera (ABCL) Biologics announced that it has commenced an underwritten public offering of $200M of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to…
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants.
AbCellera price target raised to $30 from $12 at Truist
Truist raised the firm’s price target on AbCellera (ABCL) to $30 from $12 and keeps a Buy rating on the shares. The company reported Phase 2 4-week VMS data that…
AbCellera price target raised to $25 from $13 at JonesResearch
JonesResearch analyst Debanjana Chatterjee raised the firm’s price target on AbCellera (ABCL) to $25 from $13 and keeps a Buy rating on the shares. The Phase 2 study of ABCL635…
AbCellera Biologics Slides: Corporate presentation
AbCellera Biologics has posted slides in relation to its latest quarterly earnings report, which was published on August 10, 2026.
AbCellera Biologics Transcript: Study result
Phase II data for ABCL635 in moderate to severe vasomotor symptoms showed robust efficacy, with significant reductions in symptom frequency and severity, high rates of complete resolution, and a favorable safety profile. The once-monthly injectable offers strong differentiation from current therapies and addresses a major unmet need.
AbCellera Biologics Press release: Study result
AbCellera Biologics issued a press release on August 10, 2026, disclosing material business information to investors.
AbCellera Biologics Slides: Study result
AbCellera Biologics has posted slides in relation to its latest quarterly earnings report, which was published on August 10, 2026.
This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News.
New data show a single dose of AbCellera's menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes.
AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise
AbCellera said Monday its experimental menopause treatment significantly reduced the frequency and severity of hot flashes in a mid-stage trial, sending its shares up 24% in premarket trading.
AbCellera announces Phase 1/2 trial of ABCL635 met primary efficacy endpoints
AbCellera (ABCL) announced positive top-line results from the Phase 2 portion of its Phase 1/2 clinical trial evaluating ABCL635, an investigational neurokinin 3 receptor, NK3R, antagonist antibody. A...
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635.
AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Aug. 10...
AbCellera price target raised to $9 from $8 at Stifel
Stifel raised the firm’s price target on AbCellera (ABCL) to $9 from $8 and keeps a Buy rating on the shares.
AbCellera price target raised to $12 from $11 at Cantor Fitzgerald
Cantor Fitzgerald analyst Steve Seedhouse raised the firm’s price target on AbCellera (ABCL) to $12 from $11 and keeps an Overweight rating on the shares.